Vikram D. Kodibagkar1,2, Praveen Kumar
Gulaka1, Federico Rojas-Quijano3, Zoltan Kovacs3,
Ralph P. Mason, 12, A Dean Sherry2,3
1Biomedical Engineering, UT Arlington
and UT Southwestern Medical Center at Dallas, Dallas, Tx, United States; 2Radiology,
UT Southwestern Medical Center at Dallas; 3Advanced Imaging
Research Center, UT Southwestern Medical Center at Dallas, Dallas, Tx
Heterogeneously
distributed hypoxic cores in tumors are known to affect radiation sensitivity
and promote development of metastases, therefore the ability to image tumor
hypoxia in vivo will provide useful prognostic information. Previous research
demonstrated that 2-nitroimidazole accumulated in hypoxic tissues due to an
enzyme mediated reduction of the nitro group in hypoxic conditions. Here we
report the in vitro and in vivo evaluation of a GdDOTA monoamide conjugate of
2-nitroimidazole, GdDO3NI, as a novel hypoxia targeting MRI T1 contrast
agent.